Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma

Fecha de publicación: Fecha Ahead of Print:

Autores organización

Autores

  • de Miguel-Perez, D
  • Pickering, EM
  • Malapelle, U
  • Grier, W
  • Pepe, F
  • Pisapia, P
  • Russo, G
  • Pinto, JA
  • Russo, A
  • Troncone, G
  • Culligan, MJ
  • Scilla, KA
  • Mehra, R
  • Mohindra, P
  • Arrieta, O
  • Del Re, M
  • Sachdeva, A
  • Hirsch, FR
  • Wolf, A
  • Friedberg, JS
  • Rolfo, C

Grupos de investigación

Resumen

Purpose: Pleural mesothelioma (PM) is an aggressive tumor still considered incurable, in part due to the lack of predictive biomarkers. Little is known about the clinical implications of molecular alterations in resectable PM tissues and blood. Here, we characterized genetic alterations to identify prognostic and predictive biomarkers in patients with resected PM.Experimental Design: Targeted next-generation sequencing was performed in retrospective pleural tumor tissue and paired plasma samples from stage IB-IIIB resected PM. Association between prognosis and presence of specific mutations was validated in silico. Results: Thirty PM tissues and paired blood samples from 12 patients were analyzed. High tissue tumor mutational burden (TMB) (>10 mutations/Mb), tissue median minor allele frequency (MAF) (>9 mutations/Mb), and blood TMB (>6 mutations/Mb), tissue KMT2C, PBRM1, PKHD1,EPHB1 and blood LIFR mutations correlated with longer disease-free survival and/or overall survival. High concordance (>80%) between tissue and blood was found for some mutations.Conclusions: Tissue TMB and MAF, blood TMB, and specific mutations correlated with outcomes in patients with resected PM and should be further studied to validate their role as prognostic biomarkers and potentially predictive factors for combinations with immune-checkpoint inhibitors. This suggest that molecular profiling could identify longer survivors in patients with resected PM.

Copyright © 2023. Published by Elsevier Ltd.

Datos de la publicación

ISSN/ISSNe:
0959-8049, 1879-0852

European Journal Of Cancer  ELSEVIER SCI LTD

Tipo:
Article
Páginas:
113457-113457

Citas Recibidas en Scopus: 1

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Resected pleural mesothelioma; Prognostic biomarkers; Tissue mutations; Blood mutations

Campos de estudio

Citar la publicación

Compartir la publicación